Key Takeaways
- • Edwards Lifesciences and Genesis Medtech agreed to pay a combined $12 million to settle FTC claims that Edwards circumvented Hart-Scott-Rodino notification requirements during its 2024 acquisition of JC Medical from Genesis.
- • The settlement addresses alleged violations of federal merger review procedures, specifically that Edwards attempted to evade the mandatory waiting period and notification process required for deals of significant size.
- • The enforcement action targets procedural compliance in M&A transactions, underscoring the FTC's focus on ensuring proper regulatory oversight of medical device sector consolidation.
- • California-based Edwards Lifesciences and Singapore-based Genesis Medtech are the parties to the settlement, with the deal underlying the violation occurring in 2024.
Summary
The Federal Trade Commission has secured a $12 million settlement with Edwards Lifesciences and Genesis Medtech over claims that Edwards attempted to evade Hart-Scott-Rodino notification and waiting period requirements during its acquisition of medical device manufacturer JC Medical in 2024.
Under the Hart-Scott-Rodino Act, companies engaged in transactions exceeding specified financial thresholds must notify the FTC and Department of Justice and observe a mandatory waiting period before closing the deal. The settlement indicates that Edwards proceeded with or structured the JC Medical acquisition in a manner that the FTC determined circumvented these procedural safeguards. The combined $12 million payment from both Edwards Lifesciences, based in California, and Singapore-based Genesis Medtech resolves the regulatory agency's enforcement action against the parties.
The case reflects heightened FTC scrutiny of consolidation activity in the medical device sector, where transaction review and competitive impact assessments are increasingly stringent. By targeting Hart-Scott-Rodino violations, the FTC emphasizes that procedural compliance in merger notifications is a non-negotiable element of deal execution, regardless of the ultimate competitive effects assessed during formal review.
Under the Hart-Scott-Rodino Act, companies engaged in transactions exceeding specified financial thresholds must notify the FTC and Department of Justice and observe a mandatory waiting period before closing the deal. The settlement indicates that Edwards proceeded with or structured the JC Medical acquisition in a manner that the FTC determined circumvented these procedural safeguards. The combined $12 million payment from both Edwards Lifesciences, based in California, and Singapore-based Genesis Medtech resolves the regulatory agency's enforcement action against the parties.
The case reflects heightened FTC scrutiny of consolidation activity in the medical device sector, where transaction review and competitive impact assessments are increasingly stringent. By targeting Hart-Scott-Rodino violations, the FTC emphasizes that procedural compliance in merger notifications is a non-negotiable element of deal execution, regardless of the ultimate competitive effects assessed during formal review.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.